|
Table 2. Risk ratio of invasive breast cancer*
Risk ratio
95% CI
Placebo
Tamoxifen
NSABP P-1 (14)
All
175
89
0.51
0.39 to 0.66
ER+
130
41
0.31
0.22 to 0.45
ER-
31
38
1.22
0.74 to 2.03
Placebo
Raloxifene
MORE (15) (invasive)
27
13
0.24
0.13 to 0.44
ER+
20
4
0.10
0.04 to 0.24
ER-
4
7
0.88
0.26 to 3.00
*CI = confidence interval; NSABP = National Surgical Adjuvant Breast and Bowel Project; ER = estrogen receptor; MORE = Multiple Outcomes of Raloxifene Evaluation.
|